Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared on X:
“2019: AstraZeneca made a multibillion-dollar bet on a novel Asia-developed drug called T-DXd. The rest is history.
2026: AstraZeneca made a multibillion-dollar bet on a novel Asia-developed drug called Ivonescimab.
History repeating itself?”
